Adil Daud, MD discusses the promising results of a new study looking at the use of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-mutated advanced melanoma.
News | September 10, 2019
The Skin Cancer Foundation’s annual Champions for Change Gala comes to The Plaza New York City October 17. The Champions for Change Gala is the signature fundraising event for The Skin Cancer Foundation’s...
Anisha B. Patel, MD discusses the latest advances in systemic treatment for melanoma with host Joshua Zeichner, MD. She reviews how treatments work, the most common cutaneous reactions patients experience, and the dermatologist's role in managing those reactions and reassuring patients that these reactions do not mean they need to stop live-saving treatment. She also discusses systemic options for non-resectable squamous cell carcinoma, as well as research into treating basal cell carcinoma. They also talk about when dermatologists should treat and when they should refer and the importance of having a good referral network.
FDA Follow-Up Study: Sunscreen Active Ingredients Are Absorbed by Bloodstream
Proscia and Johns Hopkins School of Medicine Collaborate to Bring AI Applications to High-Impact Diseases and Specialties in Pathology